Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIT with rBet v 1-FV for birch pollen–associated soy allergy
2009-011737-27Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Oct 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in soy allergy, birch pollen allergy and food allergy comparing rBet v 1-FV SCIT with Placebo SCIT (2 arms). Primary endpoints: LOAELobj (objective symptoms threshold dose) and LOAELsubj (subjective symptoms threshold dose). Started Oct 2009; status: completed.
02
Drugs
recombinant Bet v 1
03
Conditions
soy allergybirch pollen allergyfood allergy
Beyond the preview
Go deeper on 2009-011737-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011737-27.